2025-10-23 - Analysis Report
Okay, here's an analysis of Sempra (SRE) based on the data you provided, structured as requested.

## Sempra (SRE) Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** SRE
*   **Company Overview:** Sempra is a North American energy infrastructure company focused on electric and gas transmission and distribution.

**Cumulative Returns:**

*   SRE: 19.48%
*   VOO: 99.09%

**Performance Gap:**

*   Current Difference: -78.9%
*   Range: Max 13.2%, Min -92.5%
*   Relative Deviation: 12.9% (Indicates SRE's performance is near the lower end of its historical range compared to VOO.)

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 8.0%   | 70.6%  | -20.0%  | 0.0    | 34.8   |
| 2016-2018  | 11.0%  | 71.1%  | -4.0%   | 0.1    | 35.2   |
| 2017-2019  | 35.0%  | 71.1%  | 13.0%   | 0.3    | 49.3   |
| 2018-2020  | -4.0%  | 80.1%  | -28.0%  | 0.2    | 41.5   |
| 2019-2021  | -2.0%  | 80.1%  | -49.0%  | 0.4    | 43.0   |
| 2020-2022  | -15.0% | 81.1%  | -14.0%  | 0.4    | 50.3   |
| 2021-2023  | 22.0%  | 81.1%  | 20.0%   | 0.5    | 48.6   |
| 2022-2024  | 11.0%  | 81.1%  | -10.0%  | 0.6    | 57.1   |
| 2023-2025  | -10.0% | 74.5%  | -73.0%  | -0.2   | 60.1   |

**Analysis:**

Sempra has significantly underperformed the S&P 500. The relative deviation suggests this underperformance is near its historical worst. Alpha is mostly negative, indicating underperformance relative to the benchmark. The Beta values show a fluctuating correlation to the market. Notably, the most recent period (2023-2025) has a negative beta, suggesting a slight inverse correlation.

### 2. Recent Price Action

*   **Current Price:** 92.29
*   **Last-Market Data:** price: 92.06, previousClose: 92.29, change: -0.25 (Slight decrease)
*   **5-Day Moving Average:** 91.946
*   **20-Day Moving Average:** 90.7098
*   **60-Day Moving Average:** 84.951

**Analysis:**

The price is trading slightly above the 5-day and 20-day moving averages, and considerably above the 60-day moving average, suggesting a potential short-term uptrend.  The recent small price decrease could be a minor pullback.

### 3. Technical Indicators and Outlook

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI:** 60.94 (Neutral - not overbought or oversold)
*   **PPO:** -0.23 (Slightly negative, suggesting a slight downtrend)
*   **Recent (20-day) Relative Deviation Change:** -1.8 (Short-term decrease in relative performance)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (23 shares - Very Safe - MRI:0.90) Dividend_0.65 Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Expected Return:** -211.4% (Significant underperformance projected compared to S&P 500, assuming long-term, dollar-cost averaging)

**Analysis:**

The MRI suggests a medium investment recommendation. The RSI is neutral. The PPO indicates a slight downtrend. The Hybrid Signal gives conflicting signals. The recent decrease in relative deviation reinforces the negative performance against the S&P 500. Most importantly, the *very* negative Expected Return is a major red flag, indicating concerns about future underperformance compared to the broader market.

### 4. Recent News & Significant Events

*   **Positive:**
    *   BTIG Initiated Sempra at Buy.
    *   BMO Raises Price Target on Sempra to $99.
    *   Jefferies Adjusts Sempra Price Target to $89
*   **Neutral:**
    *   What You Need to Know Ahead of Sempra’s Earnings Release.
    *   NextDecade Corporation (NEXT): A Bull Case Theory - *Note: This is about NEXT, not SRE, but could indicate overall sector sentiment.*
*   **Unrelated:**
    *   EQT Reports Third Quarter 2025 Results

**Analysis:**

Recent analyst actions are mostly positive, with initiations and price target increases. This suggests analysts see potential upside. The earnings release preview indicates an upcoming catalyst for price movement.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 14
*   **Target Price:**
    *   Average: 94.14
    *   High: 106.00
    *   Low: 80.00
*   **Recent Rating Changes:** No specific recent changes listed.

**Analysis:**

The analyst consensus is "Buy," with a mean rating indicating positive sentiment.  The average target price is slightly above the current price, suggesting potential upside.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 매출      |
|--------------|-------|-----------|
| 2025-08-07   | 0.71  | 2.70 B$   |
| 2025-05-08   | 1.39  | 3.68 B$   |
| 2024-11-06   | 1.01  | 2.57 B$   |
| 2024-08-06   | 1.13  | 2.48 B$   |
| 2025-08-07   | 1.13  | 2.48 B$   |

**Analysis:**

Earnings per share (EPS) and revenue have fluctuated. The most recent EPS is lower than the previous quarter. There doesn't appear to be a clear upward trend in either EPS or revenue.

### 6. Financial Information

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $3.00B    | 46.73%        |
| 2025-03-31   | $3.80B    | 47.21%        |
| 2024-12-31   | $3.76B    | 49.23%        |
| 2024-09-30   | $2.78B    | 44.49%        |
| 2024-06-30   | $3.01B    | 44.20%        |

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $31.72B   | 1.49%    |
| 2025-03-31   | $31.66B   | 2.90%    |
| 2024-12-31   | $31.24B   | 2.16%    |
| 2024-09-30   | $29.72B   | 2.18%    |
| 2024-06-30   | $29.50B   | 2.46%    |

**Analysis:**

Revenue has fluctuated over the past several quarters. Profit margins have remained relatively stable. Equity has been increasing slightly. ROE (Return on Equity) has fluctuated, with the most recent quarter showing the lowest value.

### 7. Overall Summary

Sempra (SRE) has significantly underperformed the S&P 500. While recent analyst ratings are positive, technical indicators are mixed, and the projected long-term return is concerning. While analysts generally rate Sempra as a buy, the historical and projected performance data suggests caution.

The mixed signals from analyst ratings, combined with concerning financial figures, suggest that while analysts may be optimistic, investors should examine the risks before investing.

Let me know if you'd like any specific aspects explored further!
